Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 12/20 | 0.60 |
| ▸ | NR3C1 | P04150 | 6/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.60 |
| ▸ | PGR | P06401 | 5/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.60 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.60 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.60 |
| ▸ | AR | P10275 | 2/20 | 0.60 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.60 |
| ▸ | TNF | P01375 | 1/20 | 0.60 |
| ▸ | IL6 | P05231 | 1/20 | 0.60 |
| ▸ | GLUL | P15104 | 1/20 | 0.60 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.60 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | SHBG | P04278 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21332954 | 1.00 | HIF1A (0.60) | HIF1ANR3C1HSD17B10PGRCYP3A4 | |
| SCHEMBL35449 | 0.91 | HIF1A (0.64) | HIF1ANR3C1HSD17B10PGRCYP3A4 | |
| SCHEMBL27781029 | 0.91 | HIF1A (0.66) | HIF1ANR3C1HSD17B10PGRCYP3A4 | |
| SCHEMBL945988 | 0.90 | HIF1A (0.65) | HIF1ANR3C1HSD17B10PGRCYP3A4 | |
| SCHEMBL11068491 | 0.90 | HIF1A (0.62) | HIF1ANR3C1HSD17B10PGRCYP3A4 | |
| SCHEMBL264554 | 0.90 | HIF1A (0.64) | HIF1ANR3C1HSD17B10PGRCYP3A4 | |
| SCHEMBL677626 | 0.89 | HIF1A (0.61) | HIF1ANR3C1HSD17B10PGRCYP3A4 | |
| SCHEMBL2326922 | 0.89 | HIF1A (0.63) | HIF1ANR3C1HSD17B10PGRCYP3A4 | |
| SCHEMBL28480766 | 0.89 | HIF1A (0.67) | HIF1ANR3C1HSD17B10PGRCYP3A4 | |
| SCHEMBL5955148 | 0.88 | HIF1A (0.62) | HIF1ANR3C1HSD17B10PGRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107427584-A | Joint fat pad preparation and its application method | 阿勒根公司 | 2017-12-01 | — | — | CN | claimed |
| CN-101060831-A | Conveniently implantable sustained release pharmaceutical composition | RAMSCOR INC (US) | 2007-10-24 | — | — | CN | claimed |
| EP-1829527-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-09-05 | — | — | EP | claimed |
| EP-1829528-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-09-05 | — | — | EP | claimed |
| EP-1815846-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-08-08 | — | — | EP | claimed |
| EP-1815847-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-08-08 | — | — | EP | claimed |
| CN-1703199-A | Aggregate with enhanced deformability comprising at least three amphiphiles for improved transport through a semi-permeable barrier and use of non-invasive drugs in vivo, in particular through the skin | IDEA AG (DE) | 2005-11-30 | — | — | CN | claimed |
| EP-1551370-A1 | AGGREGATE WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN | IDEA AG (DE) | 2005-07-13 | — | — | EP | claimed |
| US-20040105881-A1 | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2004-06-03 | — | — | US | claimed |
| WO-2004032900-A1 | AGGREGATE WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN | IDEA AG (DE) | 2004-04-22 | — | — | WO | claimed |
| CN-118355029-A | Methods of treating diffuse large B-cell lymphomas using anti-CD 79B immunoconjugates | 基因泰克公司 | 2024-07-16 | — | — | CN | disclosed |
| EP-4380978-A1 | METHODS OF USING ANTI-CD79B IMMUNOCONJUGATES TO TREAT DIFFUSE LARGE B-CELL LYMPHOMA | Genentech, Inc. (US) | 2024-06-12 | — | — | EP | disclosed |
| US-20230099756-A1 | METHODS OF USING ANTI-CD79B IMMUNOCONJUGATES TO TREAT DIFFUSE LARGE B-CELL LYMPHOMA | GENENTECH, INC. (US) | 2023-03-30 | — | — | US | disclosed |
| WO-2023019092-A1 | METHODS OF USING ANTI-CD79B IMMUNOCONJUGATES TO TREAT DIFFUSE LARGE B-CELL LYMPHOMA | GENENTECH, INC. (US) | 2023-02-16 | — | — | WO | disclosed |
| CN-107427584-A | Joint fat pad preparation and its application method | 阿勒根公司 | 2017-12-01 | — | — | CN | disclosed |
| CN-104334196-A | Histidyl-trna synthetases for treating autoimmune and inflammatory diseases | ATYR PHARMA INC | 2015-02-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230099756-A1 | METHODS OF USING ANTI-CD79B IMMUNOCONJUGATES TO TREAT DIFFUSE LARGE B-CELL LYMPHOMA | CD79B, CD99, BCL6 | HIF1A 4135/4885NR3C1 624/4885HSD17B10 2069/4885 |
| US-20040105881-A1 | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | CUTA, ABCG2, PIGS | HIF1A 3394/4885NR3C1 1903/4885HSD17B10 3257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.